Background: The effect of chronic hepatitis B (CHB) treatment on hepatocyte apoptosis has not been evaluated. We investigated the changes in serum levels of the apoptotic caspase-generated fragments of keratin-18 (K-18) in hepatitis B e antigen (HBeAg)-negative CHB patients under nucleoside/nucleotide analogue(s). Methods: We included 46 patients with HBeAg-negative CHB who had received lamivudine or adefovir monotherapy for ≥12 months. Of the 42 lamivudine treated patients, 23 developed virological breakthroughs and received add-on adefovir therapy for ≥12 months. Levels of K-18 fragments were measured blindly in stored serum samples using the M30-Apoptosense® ELISA Kit (PEVIVA, Alexis, Grünwald, Germany). Conclusions: Serum levels of K-18 fragments decrease significantly during oral antiviral therapy in HBeAgnegative CHB in parallel with the improvements in ALT and HBV DNA levels. They increased again during breakthroughs and improved after an effective rescue therapy, perhaps at a slower rate compared to the initial therapy.
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Conclusions: Serum levels of K-18 fragments decrease significantly during oral antiviral therapy in HBeAgnegative CHB in parallel with the improvements in ALT and HBV DNA levels. They increased again during breakthroughs and improved after an effective rescue therapy, perhaps at a slower rate compared to the initial therapy.
The development of oral nucleoside/nucleotide analogues has revolutionized the treatment of chronic hepatitis B (CHB) offering chances for long-term inhibition of viral replication in the vast majority of patients [1, 2] . The frequent emergence of viral resistance was the major limitation of such therapy with the first-generation agents, mostly with lamivudine, but the rates of resistance have now been minimized with the introduction of newer and more potent agents, such as entecavir and tenofovir [1, 2] . Currently, one of the most important unanswered questions for long-term oral antiviral therapy in CHB is whether treatment can be safely discontinued after some years of successful control of viral replication, particularly in patients with hepatitis B e antigen (HBeAg)-negative CHB [1, 2] . In addition, although effective oral antiviral therapy has been shown not only to inhibit viral replication but also to improve liver histology and severity of liver disease, it cannot eliminate the risk of hepatocellular carcinoma (HCC) [3] . Thus, the evaluation of the effects of such therapy on mechanisms of hepatocyte death, such as apoptosis, might provide useful information.
Apoptosis represents a well-known mechanism of cell death involved in acute and chronic liver injury [4] not only from HBV [5] [6] [7] but also from most causes of liver disease [8] [9] [10] . Apoptotic liver cell death in viral hepatitis is recognized as an antiviral mechanism of the host infected liver cells in order to prevent the infection of new healthy hepatocytes and control viral replication [11] . Caspases, a family of intracellular cysteine
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Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy Introduction proteolytic enzymes, play a central role in the apoptotic liver cell death cleaving a variety of cellular substrates and leading to cell fragmentation and phagocytosis [12] . One of the substrates of caspases in the liver is keratin-18 (K-18), a major intermediate filament protein of the cytoskeleton [13, 14] . The cleavage of K-18 by caspases 3, 7 and 9 at two conserved aspartatic acid residues during apoptosis results in the production of a neoepitope of K-18 at Asp396, which is not present in healthy or necrotic cells [15] . The measurement of the levels of caspase-generated fragments of K-18 in serum by an ELISA has become the most reliable method of indirect quantification of liver cell apoptosis [15] [16] [17] . In particular, in HBeAg-negative chronic HBV infection, we have previously shown that serum levels of K-18 fragments are strongly associated with their immunohistochemical hepatic expression and presence of liver injury expressed by aminotransferases, serum HBV DNA levels and histological grading score [18] .
The aim of this study was to investigate the changes of serum levels of apoptotic caspase-generated fragments of K-18 in patients with HBeAg-negative CHB treated with long-term oral antiviral therapy with nucleoside/ nucleotide analogues.
Methods

Patient population
In total, 46 consecutive adult nucleoside/nucleotidenaive patients with HBeAg-negative CHB seen at our liver clinics between January and December 2006 were included in the study. The diagnosis of HBeAg-negative CHB was based on positive hepatitis B surface antigen (HBsAg), negative HBeAg and positive antibody against HBeAg for ≥6 months, increased alanine aminotransferase (ALT) activity (higher than the upper limit of normal [ULN]) on ≥2 separate monthly determinations within the last 6 months, serum HBV DNA >2,000 IU/ ml, compatible liver histological lesions and exclusion of other causes of liver injury, including current alcohol abuse. Patients with decompensated liver disease, HCC or any other malignancy, history of liver transplantation or coinfection with hepatitis D virus, HCV or HIV were excluded. The study was approved by the hospital ethics committee.
Oral antiviral therapy and follow-up
Of the 46 patients, 42 were initially treated with lamivudine monotherapy at a daily dose of 100 mg and 4 with adefovir dipivoxil monotherapy at a daily dose of 10 mg. Patients with virological breakthroughs under lamivudine received lamivudine and adefovir combination therapy.
All patients underwent liver biopsy within 6 months before treatment initiation. Epidemiological and anthropometrical characteristics, abdominal ultrasound, serological markers and routine laboratory data including α-fetoprotein were obtained before treatment, while routine laboratory tests were repeated at least every 3 months during therapy. Serum HBV DNA levels were measured before treatment and at least every 6 months during treatment. Serum samples were stored every time a blood test was obtained.
Definitions
Initial virological response was considered to be present in patients with undetectable HBV DNA within the first 6-12 months of treatment, and maintained virological response in patients with initial virological response that was maintained throughout therapy. Primary virological non-response was considered to be present in patients with a serum HBV DNA drop of <1 log 10 IU/ml at 3 months of therapy. Virological breakthrough was defined as the reappearance of serum HBV DNA in patients with previous HBV DNA undetectability or the increase of serum HBV DNA of ≥1 log 10 compared to the treatment nadir. Biochemical response was defined as the normalization of ALT (<ULN) and biochemical breakthrough as the increase of ALT to abnormal levels after previous biochemical response. The ULN of ALT was 40 IU/l for both males and females.
Current alcohol abuse was defined as average daily alcohol consumption of >30 g for males or >20 g for females during the last 12 months. The exclusion of patients with HCC was based on abdominal ultrasound and α-fetoprotein levels.
Methods
Commercially available assays were used for all haematological, biochemical and serological determinations. Serum HBV DNA levels were determined using a sensitive in-house real-time PCR assay as described previously [19] . The sensitivity of the test was 45 IU/ml.
The levels (U/l) of caspase-generated K-18 fragments were measured blindly in serum samples taken before treatment that had been stored at -80 ο C, at 6 and 12 months of treatment, at the detection of virological breakthrough, if any, and at 6 and 12 months after the detection of virological breakthrough. For this determination, we used the M30-Apoptosense ® ELISA assay (PEVIVA, Alexis, Grünwald, Germany), which was designed to detect specifically apoptosis of K-18-positive cells in human serum and plasma and to measure quantitatively the apoptosis-associated neoepitope in the C-terminal domain of K-18 (amino acids 387-396) [8] .
All 46 liver biopsies had an adequate specimen with length ≥1.5 cm and were evaluated by a single liver histopathologist. The histological changes were classified according to the classification proposed by Ishak et al. [20] . Histological findings compatible with CHB were considered to be present in cases with grading score ≥4 and/or a staging score ≥2.
Overall, 10 of the 46 patients underwent a repeat liver biopsy being in virological remission after a median (range) of 12 months (12-16) of initial therapy. In both pre-therapy and on-therapy liver biopsies of these 10 patients, caspase-cleaved K-18 fragments were detected by immunohistochemistry on 5-µm-thick paraffin sections using the mouse monoclonal antibody M30 CytoDeath (Roche Diagnostics, Mannheim, Germany), as previously described in detail [18] . Immunostained sections were evaluated by two observers. Hepatocytes with specific cytoplasmic positivity for M30 antibody were counted at a ×40 magnification on the whole tissue section. Data were expressed as mean numbers of positive cells per ×40 optical field.
Statistical analysis
All data were analysed using the statistical package SPSS (version 16.0; SPSS Inc., Chicago, IL, USA). Quantitative variables were expressed as mean values ±sd or median values (range) if they had normal or abnormal distribution, respectively. Statistical analysis was performed using the Mann-Whitney test, Wilcoxon matched-paired test, corrected χ 2 test or two-tailed Fisher's exact test and Spearman correlation, when appropriate. A two-tailed P-value of <0.05 was considered to be statistically significant.
Results
The main pretreatment characteristics of the 46 patients are presented in Table 1 When only the patients with initial virological response and without virological breakthrough during the first 12 months of therapy were taken into account, K-18 fragment levels were found to decrease from baseline to 6 months or to 12 months (P<0.001) but to have no significant change from 6 to 12 months (P=0.456).
The serum levels of not only K-18 fragments but also of ALT, aspartate aminotransferase (AST) and HBV DNA decreased significantly from baseline to 6 or 12 months of therapy (P<0.001 for all comparisons; Table 2 12 months (r=0.101, P=0.594). The changes in serum levels of ALT, HBV DNA and K-18 fragments, as well as in immunohistochemically detected caspase-cleaved K-18 fragments in a representative patient with maintained on-therapy response are shown in Figure 3 .
In the 10 patients with both pre-therapy and ontherapy liver biopsies available, immunohistochemical staining showed that antiviral therapy significantly decreased the mean numbers of M30-positive cells from 0.29 ±0.14 (range 0. 10 Figure 5 ). Changes of serum K-18 fragment levels did not reach statistical significance, even when values at the onset and those at 12 months of combination therapy were compared (P=0.055).
The serum levels of K-18 fragments, ALT, AST and HBV DNA at the onset and at 6 and 12 months after the onset of combination therapy are presented in Table 3 . The changes of serum K-18 fragment levels after the onset of combination therapy correlated positively to the changes of ALT or AST levels from baseline to 6 months (r=0.585, P=0.028 or r=0.661, P=0.038) and had a trend for positive correlation from baseline to 12 months (r=0.396, P=0.068 or r=0.389, P=0.137) but not from 6 to 12 months (r=-0.151, P=0.623 or 
Discussion
The measurement of serum K-18 fragment levels by a simple ELISA has been shown to represent a reliable method of quantification of hepatic caspase activity and liver cells apoptosis [15] [16] [17] , which plays a central role in most causes of liver injury [21] . Using this method, we have previously shown that serum K-18 fragment levels are increased and strongly associated with the activity of liver disease in untreated patients with HBeAg-negative CHB and that they can be a useful serum marker for the differentiation of such patients from inactive chronic HBV carriers [18] .
The effect of antiviral therapy on hepatocyte apoptosis in patients with CHB has not been evaluated to date. Our data show that oral antiviral therapy in nucleoside/nucleotide-naive patients with HBeAgnegative CHB results in significant decrease of serum levels of apoptotic caspase-generated K-18 fragments. In our patients with HBeAg-negative CHB, serum K-18 fragment levels at 6 [18] . In fact, 39 (85%) and 40 (87%) of the 46 CHB patients had serum K-18 fragment levels after 6 and 12 months of antiviral therapy <240 U/l, which was found to represent an optimal cutoff for the differentiation of inactive carriers from HBeAg-negative CHB patients [18]. The decrease of serum K-18 fragment levels was greater during the first 6 months of therapy, when it correlated significantly to the decrease of viral load and aminotransferase activity. It should be noted that the numerically small decrease in the median serum K-18 fragment levels from 6 to 12 months of therapy might be just a statistical finding having questionable clinical significance, as K-18 fragment levels were very low already at 6 months of therapy in the majority of patients. The absence of correlations between changes of serum K-18 fragments and ALT or HBV DNA levels between 6 and 12 months of therapy may be due to the absence of significant changes of serum ALT and HBV DNA levels during this period, as the majority of patients achieve ALT normalization and HBV DNA undetectability within the first 6 months of therapy and remain so until 12 months. These findings show that oral antiviral therapy is associated with rapid reduction and probably normalization of hepatocyte apoptosis as a result of inhibition of viral replication and the consequent reduction of hepatic expression of viral antigens that represent the main stimulus for immunological attack and hepatocyte death by both necrosis and apoptosis. In a subset of our patients who underwent repeated liver biopsies remaining in virological and biochemical remission during the initial therapy, the number of cells with immunohistochemical expression of caspase-cleaved K-18 fragments was found to significantly decrease in parallel with the reductions in necroinflammatory activity and serum levels of K-18 fragments. These findings are in agreement with data from many previous studies, which have shown that oral antiviral therapy is associated with significant improvement of liver histological lesions in patients with CHB and particularly with improvements in all parameters of necroinflammatory activity including apoptosis [22, 23] . The pretreatment serum K-18 fragment levels were not found to be predictive of on-therapy development of virological breakthroughs, as they did not differ between patients remaining in remission and patients who develop breakthroughs. In contrast, in one study including patients with chronic hepatitis C, the same test was shown to predict treatment response, as the serum K-18 fragment levels were found to be significantly higher in patients with virological response compared to those without sustained virological response after interferon and ribavirin combination therapy [24] . Such a discrepancy between these two types of chronic viral hepatitis may be due to different pathogenesis and different therapeutic agents, as pure antivirals were used in our CHB patients and agents with both antiviral and immunomodulatory activities were, as usually, used in patients with chronic hepatitis C.
Virological breakthroughs were found to be associated with statistically significant increase of serum K-18 fragment levels, which remained lower compared to pretreatment values. A possible explanation for this finding might be the early diagnosis of virological breakthroughs due to the close follow-up and the prompt addition of another antiviral agent. In fact, at the onset of rescue therapy, serum HBV DNA levels were significantly lower compared to pretreatment values (P=0.002) and only 10 of the 23 (43%) patients with virological breakthroughs had developed biochemical breakthroughs as well. Only 2 of the 10 patients developed biochemical breakthroughs after the detection of virological breakthroughs, perhaps due to the 6-monthly HBV DNA determinations, and therefore reliable comments on this important subgroup cannot be drawn. Serum K-18 fragment levels increased in these two patients at the onset of virological and increased further at the development of biochemical breakthroughs, but they increased at the onset of virological breakthroughs in the majority (>80%) of such patients with or without biochemical breakthroughs. Thus, monitoring serum K-18 fragment levels using an easy and relatively cheap ELISA might be a useful strategy for the early detection of virological breakthroughs whenever the determination of serum HBV DNA is not feasible.
The addition of adefovir was followed by only a trend for decrease of serum K-18 fragment levels that was close to statistical significance only after 12 months of combination therapy (P=0.055). The lower and slower reduction of such levels after rescue than after initial therapy may be due to the different HBV strains (wild type and lamivudine resistant strains) but also due to statistical reasons. Patients with virological breakthroughs comprised one-half of the initial patients and had lower serum K-18 fragment levels at breakthroughs compared to pretreatment values, and therefore less possibility for reduction of these levels during rescue therapy. Indeed, serum K-18 fragment levels were <200 U/l in 14 of 46 (30%) patients before treatment and 13 of 23 (56.5%) patients at breakthroughs, whereas they were not significantly different after 12 months of therapy in both groups (P=0.252). Similarly to the initial therapy, the decrease of serum K-18 fragment levels after rescue therapy correlated to the decrease of ALT and AST as well as of serum HBV DNA levels.
In conclusion, our study shows that serum levels of apoptotic caspase-generated K-18 fragments decrease significantly and rapidly during oral antiviral therapy in HBeAg-negative CHB in parallel with the improvements in ALT, AST and serum HBV DNA levels. They increase again during virological breakthrough and decrease after an effective rescue therapy. Serum K-18 fragment levels may decrease at a slower rate after rescue than after initial therapy, but this observation needs further evaluation. The decrease and almost normalization of hepatocyte apoptosis during effective oral antiviral therapy is probably associated with significant histological improvement. It should be kept in mind, however, that the reduction or inhibition of apoptosis, which is an important mechanism of cell death, could theoretically have undesirable effects, as it may result in prolongation of the halflife of infected hepatocytes and therefore might delay viral eradication and even preserve some potential for hepatocarcinogenesis.
